[Form 4] Veracyte, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Veracyte Director Evan Jones received a grant of 9,321 restricted stock units (RSUs) on June 18, 2025. Following this transaction, Jones beneficially owns a total of 43,664 shares directly.

Key terms of the RSU grant:

• RSUs vest in full on the first anniversary of the grant date
• Alternative vesting occurs immediately prior to the company's next annual stockholder meeting, if earlier
• Accelerated vesting provision triggers upon a change in control
• Grant price: $0

The Form 4 was filed on June 23, 2025, within the required reporting window. The transaction was executed under transaction code 'A' indicating an acquisition of securities. This equity grant appears to be part of the company's director compensation program.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

JONES EVAN/ FA

(Last) (First) (Middle)

6000 SHORELINE COURT

SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VERACYTE, INC. [ VCYT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/18/2025		A(1)		9,321	A	$0	43,664	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted stock units awarded on June 18, 2025 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer.

Remarks:

	/s/ Jonathan Wygant as attorney-in-fact	06/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many restricted stock units (RSUs) did VCYT director Evan Jones receive on June 18, 2025?

According to the Form 4 filing, VCYT director Evan Jones received 9,321 restricted stock units (RSUs) on June 18, 2025 at a price of $0.

What are the vesting terms for VCYT director Evan Jones's June 2025 RSU grant?

The RSUs vest in full on either: 1) the first anniversary of the grant date (June 18, 2026), or 2) immediately prior to VCYT's next annual meeting of stockholders, whichever comes earlier. Additionally, the RSUs will fully vest if there is a change in control of the company.

How many VCYT shares does Evan Jones own after the June 2025 RSU grant?

Following the RSU grant transaction, Evan Jones directly owns 43,664 shares of VCYT common stock.

Who filed the Form 4 for VCYT director Evan Jones?

The Form 4 was signed by Jonathan Wygant as attorney-in-fact for Evan Jones on June 23, 2025.

What is Evan Jones's role at VCYT according to the Form 4?

According to the Form 4 filing, Evan Jones serves as a Director of Veracyte, Inc. (VCYT), as indicated by the 'X' marked in the Director box under the Relationship of Reporting Person(s) to Issuer section.